JP2013533232A5 - - Google Patents

Download PDF

Info

Publication number
JP2013533232A5
JP2013533232A5 JP2013514194A JP2013514194A JP2013533232A5 JP 2013533232 A5 JP2013533232 A5 JP 2013533232A5 JP 2013514194 A JP2013514194 A JP 2013514194A JP 2013514194 A JP2013514194 A JP 2013514194A JP 2013533232 A5 JP2013533232 A5 JP 2013533232A5
Authority
JP
Japan
Prior art keywords
composition
cancer
composition according
agent
taxane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013514194A
Other languages
English (en)
Japanese (ja)
Other versions
JP6031437B2 (ja
JP2013533232A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/037450 external-priority patent/WO2011156119A1/en
Publication of JP2013533232A publication Critical patent/JP2013533232A/ja
Publication of JP2013533232A5 publication Critical patent/JP2013533232A5/ja
Application granted granted Critical
Publication of JP6031437B2 publication Critical patent/JP6031437B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013514194A 2010-06-07 2011-05-20 増殖性疾患を処置するための組み合わせ療法 Active JP6031437B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US35233310P 2010-06-07 2010-06-07
US61/352,333 2010-06-07
US201161446909P 2011-02-25 2011-02-25
US61/446,909 2011-02-25
PCT/US2011/037450 WO2011156119A1 (en) 2010-06-07 2011-05-20 Combination therapy methods for treating proliferative diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016132221A Division JP2016175947A (ja) 2010-06-07 2016-07-04 増殖性疾患を処置するための組み合わせ療法

Publications (3)

Publication Number Publication Date
JP2013533232A JP2013533232A (ja) 2013-08-22
JP2013533232A5 true JP2013533232A5 (https=) 2014-07-03
JP6031437B2 JP6031437B2 (ja) 2016-11-24

Family

ID=45098373

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2013514194A Active JP6031437B2 (ja) 2010-06-07 2011-05-20 増殖性疾患を処置するための組み合わせ療法
JP2016132221A Withdrawn JP2016175947A (ja) 2010-06-07 2016-07-04 増殖性疾患を処置するための組み合わせ療法
JP2018025928A Pending JP2018087227A (ja) 2010-06-07 2018-02-16 増殖性疾患を処置するための組み合わせ療法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016132221A Withdrawn JP2016175947A (ja) 2010-06-07 2016-07-04 増殖性疾患を処置するための組み合わせ療法
JP2018025928A Pending JP2018087227A (ja) 2010-06-07 2018-02-16 増殖性疾患を処置するための組み合わせ療法

Country Status (20)

Country Link
US (4) US20140155344A1 (https=)
EP (2) EP3056201A1 (https=)
JP (3) JP6031437B2 (https=)
KR (1) KR101850566B1 (https=)
CN (2) CN105832703A (https=)
AU (2) AU2011264590B2 (https=)
BR (1) BR112012031163A2 (https=)
CA (1) CA2801891C (https=)
CO (1) CO6670568A2 (https=)
CR (1) CR20120638A (https=)
IL (2) IL223190A0 (https=)
MX (1) MX2012014231A (https=)
MY (1) MY166014A (https=)
NI (1) NI201200181A (https=)
NZ (1) NZ707377A (https=)
PH (1) PH12012502399A1 (https=)
RU (2) RU2577278C2 (https=)
SG (2) SG185798A1 (https=)
WO (1) WO2011156119A1 (https=)
ZA (1) ZA201208820B (https=)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
CA2509365C (en) 2002-12-09 2012-08-07 American Bioscience, Inc. Compositions and methods of delivery of pharmacological agents
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
KR20070114753A (ko) 2005-02-18 2007-12-04 아브락시스 바이오사이언스 인크. 치료제의 조합 및 투여 방식, 및 조합 요법
LT3311805T (lt) 2005-08-31 2020-04-27 Abraxis Bioscience, Llc Kompozicijos, apimančios silpnai vandenyje tirpius farmacinius agentus ir priešmikrobinius agentus
EP3470071A1 (en) 2006-12-14 2019-04-17 Abraxis BioScience, LLC Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
JP5579057B2 (ja) * 2007-06-01 2014-08-27 アブラクシス バイオサイエンス, エルエルシー 再発性癌の処置のための方法および組成物
PT2419732T (pt) 2009-04-15 2019-12-24 Abraxis Bioscience Llc Composições e métodos de nanopartículas isentas de priões
NZ602382A (en) 2010-03-26 2014-11-28 Abraxis Bioscience Llc Methods of treatment of hepatocellular carcinoma
MX2012011155A (es) 2010-03-29 2012-12-05 Abraxis Bioscience Llc Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos.
EP3141245A1 (en) 2010-03-29 2017-03-15 Abraxis BioScience, LLC Methods of treating cancer
MX347225B (es) 2010-06-04 2017-04-19 Abraxis Bioscience Llc * Metodos de tratamiento contra el cancer pancreatico.
JP6031437B2 (ja) * 2010-06-07 2016-11-24 アブラクシス バイオサイエンス, エルエルシー 増殖性疾患を処置するための組み合わせ療法
KR101970342B1 (ko) 2011-04-28 2019-04-18 아브락시스 바이오사이언스, 엘엘씨 나노입자 조성물의 혈관내 전달 및 그의 용도
MX374963B (es) 2011-04-29 2025-03-06 Selecta Biosciences Inc Nanoportadores sintéticos tolerogénicos para reducir las respuestas de anticuerpos.
AU2012253571A1 (en) 2011-05-09 2014-01-09 Mayo Foundation For Medical Education And Research Cancer treatments
TW201700103A (zh) 2011-11-01 2017-01-01 西建公司 利用胞嘧啶核苷類似物之口服配方治療癌症的方法
EP3560486A1 (en) 2011-12-14 2019-10-30 Abraxis BioScience, LLC Use of polymeric excipients for lyophilization or freezing of particles
US10413606B2 (en) 2012-10-01 2019-09-17 Mayo Foundation For Medical Education And Research Methods for treating cancer with nanoparticle complexes of albumin-bound paclitaxel and anti-VEGF antibodies
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
EP3698784A1 (en) 2013-03-12 2020-08-26 Abraxis BioScience, LLC Methods of treating lung cancer
RU2015143490A (ru) 2013-03-14 2017-04-26 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечения рака мочевого пузыря
BR122020023215B1 (pt) * 2013-05-03 2022-11-22 Selecta Biosciences, Inc Composição e kit de nanocarreadores sintéticos tolerogênicos para reduzir ou prevenir anafilaxia em resposta a um antígeno não alergênico
AU2014262164B2 (en) * 2013-05-03 2020-02-27 Selecta Biosciences, Inc. Dosing combinations for reducing undesired humoral immune responses
EP3154586B1 (en) 2014-06-13 2020-05-27 Mayo Foundation for Medical Education and Research Treating lymphomas
KR20170020371A (ko) 2014-06-16 2017-02-22 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 골수종의 치료
WO2015195634A1 (en) * 2014-06-17 2015-12-23 Celgne Corporation Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
JP7242180B2 (ja) 2014-09-07 2023-03-20 セレクタ バイオサイエンシーズ インコーポレーテッド 抗ウイルス導入ベクター免疫応答を減弱化するための方法および組成物
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
BR112017011536A2 (pt) * 2014-12-02 2018-02-27 Celgene Corp terapias de combinação
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
ES3009356T3 (en) 2015-06-29 2025-03-26 Abraxis Bioscience Llc Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體-抗體組合物及其製造及使用方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
WO2017120501A1 (en) 2016-01-07 2017-07-13 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon
CN105606824B (zh) * 2016-01-28 2018-04-06 山东省药物研究院 晚期乳腺癌患者外周血循环肿瘤细胞Her‑2基因的检测方法
WO2017139698A1 (en) 2016-02-12 2017-08-17 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
EP3432928A4 (en) 2016-03-21 2019-11-20 Mayo Foundation for Medical Education and Research PROCESS FOR IMPROVING THE THERAPEUTIC INDEX FOR CHEMOTHERAPEUTIC
EP3432926A4 (en) 2016-03-21 2019-11-20 Mayo Foundation for Medical Education and Research METHOD FOR REDUCING THE TOXICITY OF CHEMOTHERAPEUTICS
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
WO2018045239A1 (en) 2016-09-01 2018-03-08 Mayo Foundation For Medical Education And Research Carrier-pd-l1 binding agent compositions for treating cancers
JP2019526579A (ja) 2016-09-01 2019-09-19 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチMayo Foundation For Medical Education And Research T細胞癌を標的とする為の方法及び組成物
RU2021128415A (ru) 2016-09-06 2021-11-08 Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч Композиции с паклитакселом, альбумином и связывающим средством и способы их применения и получения
KR20230011473A (ko) 2016-09-06 2023-01-20 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 Pd-l1 발현 암의 치료 방법
EP3509635A1 (en) 2016-09-06 2019-07-17 Vavotar Life Sciences LLC Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
CA3039582A1 (en) * 2016-10-07 2018-04-12 Abraxis Bioscience, Llc Methods of treating biliary tract cancer
ES3036482T3 (en) 2017-03-11 2025-09-19 Cartesian Therapeutics Inc Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
KR20250057947A (ko) 2017-10-03 2025-04-29 크리티테크, 인크. 암의 치료를 위한 면역치료제의 전신 전달과 조합된 항신생물성 입자의 국소 전달
IL277402B1 (en) 2018-03-20 2026-04-01 Abraxis Bioscience Llc Methods for treating central nervous system disorders using administration of MTOR inhibitor nanoparticles and albumin
CN108498529A (zh) * 2018-06-20 2018-09-07 福建师范大学 用于肿瘤预防治疗的DNA甲基转移酶抑制剂与cGAMP药物组合物
US20220008383A1 (en) * 2018-11-13 2022-01-13 Amy Yee Compositions and methods of enhancing immunotherapies
MX2021014686A (es) 2019-05-29 2022-04-06 Nelum Corp Métodos y usos para tratar el cáncer.
AU2020287627A1 (en) 2019-06-04 2021-11-18 Selecta Biosciences, Inc. Formulations and doses of PEGylated uricase
BR112022007710A2 (pt) 2019-10-28 2022-07-12 Abraxis Bioscience Llc Composições farmacêuticas de albumina e rapamicina
WO2022034489A1 (en) * 2020-08-11 2022-02-17 Auxilla Pharmaceuticals And Research Llp A non-aqueous suspension of anticancer agent
TR202018770A2 (tr) * 2020-11-23 2021-02-22 Ankara Ueniversitesi Platine Dirençli Over Kanseri Tedavisine Yönelik Yeni Bir İlaç Taşıyıcı Sistem

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
PT1023050E (pt) * 1997-06-27 2013-12-04 Abraxis Bioscience Llc Novas formulações de agentes farmacológicos, métodos para a sua preparação e métodos para a sua utilização
US6613753B2 (en) * 2001-02-21 2003-09-02 Supergen, Inc. Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
CA2509365C (en) 2002-12-09 2012-08-07 American Bioscience, Inc. Compositions and methods of delivery of pharmacological agents
US7951780B2 (en) * 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
US20050187148A1 (en) * 2004-02-25 2005-08-25 Yoshinori Naoe Antitumor agent
AU2006249235B2 (en) * 2004-05-14 2010-11-11 Abraxis Bioscience, Llc Sparc and methods of use thereof
US20060069060A1 (en) * 2004-09-27 2006-03-30 Sanjeev Redkar Salts of decitabine
JP5156392B2 (ja) * 2005-02-03 2013-03-06 トポターゲット ユーケー リミテッド Hdac阻害剤を用いる併用療法
US20070166388A1 (en) 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
US8735394B2 (en) * 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
KR20070114753A (ko) * 2005-02-18 2007-12-04 아브락시스 바이오사이언스 인크. 치료제의 조합 및 투여 방식, 및 조합 요법
EP3527202A1 (en) 2005-08-31 2019-08-21 Abraxis BioScience, LLC Compositions and methods for preparation of poorly water soluble drugs with increased stability
JP2009514879A (ja) * 2005-11-04 2009-04-09 メルク エンド カムパニー インコーポレーテッド Saha、カルボプラチン及びパクリタキセルを用いて癌を治療する方法及びその他の併用療法
US20080057086A1 (en) * 2006-09-01 2008-03-06 Pharmion Corporation Colon-targeted oral formulations of cytidine analogs
US8093220B2 (en) * 2006-12-04 2012-01-10 Novartis Ag Combination of an HDAC inhibitor and an antimetabolite
US20100166869A1 (en) 2007-05-03 2010-07-01 Desai Neil P Methods and compositions for treating pulmonary hypertension
AU2009251848A1 (en) * 2008-04-03 2009-12-03 Cognate 3, Llc Compositions and methods for immunotherapy
TW200942233A (en) 2008-04-10 2009-10-16 Abraxis Bioscience Llc Compositions of hydrophobic taxane derivatives and uses thereof
MX2010011165A (es) 2008-04-10 2011-02-22 Abraxis Bioscience Llc Composiciones de derivados de taxano hidrofobos y sus usos.
PL3692983T3 (pl) * 2008-05-15 2021-12-27 Celgene Corporation Doustne formulacje analogów cytydyny i sposoby ich zastosowania
US20100055047A1 (en) * 2008-08-26 2010-03-04 Yiyu Zou Methods for treating bronchial premalignancy and lung cancer
CA2746129A1 (en) * 2008-12-11 2010-06-17 Abraxis Bioscience, Llc Combination chemotherapy of nanoparticulate taxanes and inhibitors of pro-survival and/or inflammatory signals
EP3103452A1 (en) * 2009-08-25 2016-12-14 Abraxis BioScience, LLC Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors
MX2012011155A (es) * 2010-03-29 2012-12-05 Abraxis Bioscience Llc Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos.
EP3141245A1 (en) * 2010-03-29 2017-03-15 Abraxis BioScience, LLC Methods of treating cancer
CA2801314A1 (en) * 2010-06-02 2011-12-08 Abraxis Bioscience, Llc Methods of treating bladder cancer
MX347225B (es) * 2010-06-04 2017-04-19 Abraxis Bioscience Llc * Metodos de tratamiento contra el cancer pancreatico.
JP6031437B2 (ja) * 2010-06-07 2016-11-24 アブラクシス バイオサイエンス, エルエルシー 増殖性疾患を処置するための組み合わせ療法
US9149455B2 (en) * 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) * 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer

Similar Documents

Publication Publication Date Title
JP2013533232A5 (https=)
JP2013527232A5 (https=)
RU2012156903A (ru) Способы комбинированной терапии для лечения пролиферативных заболеваний
Sun et al. Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system
Socinski et al. Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer
JP2011079858A5 (https=)
Socinski et al. Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer
NZ708506A (en) Methods of treating bladder cancer
JP2013503174A5 (https=)
Wang et al. Gold nanoparticle-mediated delivery of paclitaxel and nucleic acids for cancer therapy
Pham et al. Strategies for the design of orally bioavailable antileishmanial treatments
MX2012011155A (es) Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos.
JP2015516989A5 (https=)
JP2008530248A5 (https=)
JP2010209081A5 (https=)
HRP20160609T1 (hr) Postupci liječenja hepatocelularnog karcinoma
JP2015524444A5 (https=)
RU2017132877A (ru) Комбинация антагониста pd-1 и эрибулина для лечения рака
JP2009515901A5 (https=)
JP2019530706A5 (https=)
JP2014520874A5 (https=)
CN107073015B (zh) 用于治疗吸烟者中的非小细胞肺癌的维利帕尼与卡铂和紫杉醇的组合
JP2015510945A5 (https=)
RU2015139515A (ru) Комбинированное лечение
JP2013541582A5 (https=)